Role of biomarkers to predict outcomes and response to therapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Biomarkers
Urinary Bladder
Carcinoma
Neoadjuvant Therapy
Urinary Bladder Neoplasms
Therapeutics
Recurrence
Mortality

Keywords

  • Bladder cancer
  • Molecular markers

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Role of biomarkers to predict outcomes and response to therapy. / Lotan, Yair.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 1, 01.2010, p. 97-101.

Research output: Contribution to journalArticle

@article{e2b53d5785e44548979082a46e9a96dd,
title = "Role of biomarkers to predict outcomes and response to therapy",
abstract = "Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.",
keywords = "Bladder cancer, Molecular markers",
author = "Yair Lotan",
year = "2010",
month = "1",
doi = "10.1016/j.urolonc.2009.03.017",
language = "English (US)",
volume = "28",
pages = "97--101",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Role of biomarkers to predict outcomes and response to therapy

AU - Lotan, Yair

PY - 2010/1

Y1 - 2010/1

N2 - Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.

AB - Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.

KW - Bladder cancer

KW - Molecular markers

UR - http://www.scopus.com/inward/record.url?scp=72549108182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549108182&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.03.017

DO - 10.1016/j.urolonc.2009.03.017

M3 - Article

C2 - 20123357

AN - SCOPUS:72549108182

VL - 28

SP - 97

EP - 101

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -